Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
P 1 (1)

Trial Status

Active Not Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT03610711Phase 1Active Not Recruiting

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

NCT04507750Not ApplicableUnknownPrimary

Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer

Showing all 2 trials

Research Network

Activity Timeline